España
India
Italia
대한민국
日本
My Account
Benzinga Edge
Benzinga Research
Benzinga Pro
Login
Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Harmony Biosciences
HRMY
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$39.54
0.72
1.85%
At close: -
$39.54
0.00
0.00%
After Hours: 4:00 PM EDT
Get Report
Comment
Harmony Biosciences (HRMY) Forecast
News
Earnings
Harmony Biosciences (HRMY) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Harmony Biosciences (NASDAQ:HRMY) Stock
Harmony Biosciences Stock (NASDAQ: HRMY)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Monday, January 27, 2025
HC Wainwright & Co. Reiterates Buy on Harmony...
Benzinga Newsdesk
Thursday, January 16, 2025
A Glimpse Into The Expert Outlook On Harmony Biosciences Through 7 Analysts
Benzinga Insights
HC Wainwright & Co. Reiterates Buy on Harmony...
Benzinga Newsdesk
Monday, January 13, 2025
Needham Reiterates Buy on Harmony Biosciences...
Benzinga Newsdesk
Harmony Biosciences Reports $714M 2024 Revenu...
Benzinga Newsdesk
Tuesday, December 17, 2024
HC Wainwright & Co. Initiates Coverage On Har...
Benzinga Newsdesk
Thursday, October 31, 2024
Reported Earlier, Harmony Biosciences Shareho...
Benzinga Newsdesk
Wednesday, October 30, 2024
Why Harmony Biosciences (HRMY) Stock Is Down 18% Today
Henry Khederian
Harmony Biosciences shares are trading lower ...
Benzinga Newsdesk
Cantor Fitzgerald Maintains Overweight on Har...
Benzinga Newsdesk
Oppenheimer Reiterates Outperform on Harmony ...
Benzinga Newsdesk
Needham Reiterates Buy on Harmony Biosciences...
Benzinga Newsdesk
Tuesday, October 29, 2024
Harmony Biosciences Reports Commencement Of P...
Benzinga Newsdesk
Harmony Biosciences Holdings shares are tradi...
Benzinga Newsdesk
Analyst Expectations For Harmony Biosciences's Future
Benzinga Insights
Needham Reiterates Buy on Harmony Biosciences...
Benzinga Newsdesk
Harmony Biosciences Reiterated FY24 Net Produ...
Benzinga Newsdesk
Harmony Biosciences Q3 2024 Adj. EPS $1.03 Be...
Benzinga Newsdesk
Monday, October 28, 2024
Earnings Outlook For Harmony Biosciences
Benzinga Insights
Thursday, October 10, 2024
Raymond James Reinstates Outperform on Harmon...
Benzinga Newsdesk
Mizuho Maintains Outperform on Harmony Biosci...
Benzinga Newsdesk
Tuesday, October 08, 2024
Chief Commercial Officer At Harmony Biosciences Sells $1.27M Of Stock
Benzinga Insights
Wednesday, October 02, 2024
Breaking Down Harmony Biosciences: 6 Analysts Share Their Views
Benzinga Insights
Needham Reiterates Buy on Harmony Biosciences...
Benzinga Newsdesk
Tuesday, October 01, 2024
Options Exercise Update At Harmony Biosciences: Jeffrey Dierks Engages
Benzinga Insights
Tuesday, September 24, 2024
Needham Reiterates Buy on Harmony Biosciences...
Benzinga Newsdesk
Thursday, September 12, 2024
Needham Reiterates Buy on Harmony Biosciences...
Benzinga Newsdesk
Tuesday, September 10, 2024
Neurology-Focused Harmony Biosciences Gains Confidence With Wakix Sales Surge, Strategic Pipeline Expansion, Bullish Analyst Says
Vandana Singh
Unveiling 6 Analyst Insights On Harmony Biosciences
Benzinga Insights
UBS Initiates Coverage On Harmony Biosciences...
Benzinga Newsdesk
Thursday, August 08, 2024
Needham Reiterates Buy on Harmony Biosciences...
Benzinga Newsdesk
Tuesday, August 06, 2024
Analyst Expectations For Harmony Biosciences's Future
Benzinga Insights
Needham Reiterates Buy on Harmony Biosciences...
Benzinga Newsdesk
Harmony Biosciences Says On Track To Submit S...
Benzinga Newsdesk
Harmony Biosciences Reiterates 2024 Net Produ...
Benzinga Newsdesk
Harmony Biosciences Q2 2024 Adj. EPS $1.05 Be...
Benzinga Newsdesk
Monday, July 08, 2024
5 High Earnings Yield Value Stocks That You Shouldn't Ignore
Zacks
Tuesday, June 25, 2024
FDA Confirms Favorable Benefit-Risk Profile O...
Benzinga Newsdesk
Needham Reiterates Buy on Harmony Biosciences...
Benzinga Newsdesk
Monday, June 24, 2024
Needham Reiterates Buy on Harmony Biosciences...
Benzinga Newsdesk
Harmony Biosciences Announces FDA Approval Of...
Benzinga Newsdesk
Friday, June 21, 2024
A Glimpse Into The Expert Outlook On Harmony Biosciences Through 7 Analysts
Benzinga Insights
Citigroup Initiates Coverage On Harmony Biosc...
Benzinga Newsdesk
Wednesday, June 05, 2024
Harmony Biosciences Reports Data For Pitolisa...
Benzinga Newsdesk
Tuesday, May 14, 2024
Will Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs In
Nicolás Jose Rodriguez
Thursday, May 02, 2024
Looking for a Growth Stock? 3 Reasons Why Harmony Biosciences is a Solid Choice
Zacks
Wednesday, May 01, 2024
Needham Maintains Buy on Harmony Biosciences,...
Benzinga Newsdesk
Tuesday, April 30, 2024
Harmony Biosciences Holdings shares are tradi...
Benzinga Newsdesk
Harmony Biosciences Expands It CNS-Focused Pipeline With Epilepsy Candidate, Q1 Earnings Beat Street View
Vandana Singh
Key Takeaways From Harmony Biosciences Analyst Ratings
Benzinga Insights
Show More
